From symptom relief to household control: baloxavir redefines antiviral strategies for influenza.
作者信息
Xu Jin-Fu, Liu Yang, Zhang Panpan, Cao Bin
机构信息
Department of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai, 200040, China.
Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Capital Medical University, Beijing, 100054, China.
出版信息
Lancet Reg Health West Pac. 2025 Aug 2;61:101651. doi: 10.1016/j.lanwpc.2025.101651. eCollection 2025 Aug.
Abstract
摘要
相似文献
1
From symptom relief to household control: baloxavir redefines antiviral strategies for influenza.从症状缓解到家庭防控：巴洛沙韦重新定义流感抗病毒策略。
Lancet Reg Health West Pac. 2025 Aug 2;61:101651. doi: 10.1016/j.lanwpc.2025.101651. eCollection 2025 Aug.
2
Clinical efficacy of baloxavir marboxil versus oseltamivir in kidney transplant recipients with influenza.巴洛沙韦酯与奥司他韦在肾移植受者流感治疗中的临床疗效比较
Microbiol Spectr. 2025 Jul;13(7):e0295424. doi: 10.1128/spectrum.02954-24. Epub 2025 May 22.
3
Efficacy and safety of single-dose antiviral drugs for influenza treatment: A systematic review and network meta-analysis.单剂量抗病毒药物治疗流感的疗效和安全性：系统评价和网络荟萃分析。
J Med Virol. 2022 Jul;94(7):3270-3302. doi: 10.1002/jmv.27729. Epub 2022 Apr 4.
4
[A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients].[巴洛沙韦酯与神经氨酸酶抑制剂治疗健康患者流感的疗效和安全性的网络荟萃分析]
Ter Arkh. 2020 Dec 26;92(11):122-131. doi: 10.26442/00403660.2020.11.000870.
5
Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis.抗流感病毒药物用于暴露后预防：系统评价和网络荟萃分析。
Lancet. 2024 Aug 24;404(10454):764-772. doi: 10.1016/S0140-6736(24)01357-6.
6
Rapid health technology assessment of the novel endonuclease inhibitor baloxavir for the treatment of influenza.新型内切酶抑制剂 baloxavir 治疗流感的快速卫生技术评估。
J Chemother. 2024 Jul;36(4):267-282. doi: 10.1080/1120009X.2023.2263270. Epub 2023 Sep 28.
7
Household Influenza Transmission and Healthcare Resource Utilization Among Patients Treated with Baloxavir vs Oseltamivir: A United States Outpatient Prospective Survey.巴洛沙韦与奥司他韦治疗患者的家庭流感传播及医疗资源利用情况：一项美国门诊前瞻性调查
Infect Dis Ther. 2024 Apr;13(4):685-697. doi: 10.1007/s40121-024-00937-y. Epub 2024 Mar 14.
8
Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.比较使用巴洛沙韦或神经氨酸酶抑制剂治疗的流感患者的家庭传播：一项医疗保险索赔数据库研究。
Clin Infect Dis. 2021 Jun 1;72(11):e859-e867. doi: 10.1093/cid/ciaa1622.
9
Global update on the susceptibilities of influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023.2020 - 2023年流感病毒对神经氨酸酶抑制剂和帽依赖性核酸内切酶抑制剂巴洛沙韦敏感性的全球最新情况
Antiviral Res. 2025 Sep;241:106217. doi: 10.1016/j.antiviral.2025.106217. Epub 2025 Jun 24.
10
Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza.巴洛沙韦治疗在预防流感传播中的疗效
N Engl J Med. 2025 Apr 24;392(16):1582-1593. doi: 10.1056/NEJMoa2413156.
本文引用的文献
1
Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza.巴洛沙韦治疗在预防流感传播中的疗效
N Engl J Med. 2025 Apr 24;392(16):1582-1593. doi: 10.1056/NEJMoa2413156.
2
Real-world effectiveness and safety of Baloxavir Marboxil or Oseltamivir in outpatients with uncomplicated influenza A: an ambispective, observational, multi-center study.巴洛沙韦酯或奥司他韦在非复杂性甲型流感门诊患者中的真实世界有效性和安全性：一项前瞻性、观察性、多中心研究。
Front Microbiol. 2024 Jul 23;15:1428095. doi: 10.3389/fmicb.2024.1428095. eCollection 2024.
3
Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial.巴洛沙韦玛波西利与奥司他韦治疗减少流感家庭传播的效果比较：BLOCKSTONE 试验的事后分析。
Influenza Other Respir Viruses. 2024 May;18(5):e13302. doi: 10.1111/irv.13302.
4
Household Influenza Transmission and Healthcare Resource Utilization Among Patients Treated with Baloxavir vs Oseltamivir: A United States Outpatient Prospective Survey.巴洛沙韦与奥司他韦治疗患者的家庭流感传播及医疗资源利用情况：一项美国门诊前瞻性调查
Infect Dis Ther. 2024 Apr;13(4):685-697. doi: 10.1007/s40121-024-00937-y. Epub 2024 Mar 14.
5
Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: A systematic review and meta-analysis.玛巴洛沙韦与奥司他韦治疗流感病毒感染的临床疗效和安全性比较：一项系统评价和荟萃分析
J Infect Chemother. 2024 Mar;30(3):242-249. doi: 10.1016/j.jiac.2023.10.017. Epub 2023 Oct 20.
6
Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017-18 (PHIRST): a population cohort study.2017-18 年南非城乡季节性流感的无症状传播和高社区负担（PHIRST）：一项人群队列研究。
Lancet Glob Health. 2021 Jun;9(6):e863-e874. doi: 10.1016/S2214-109X(21)00141-8.
7
Influenza vaccination: protecting the most vulnerable.流感疫苗接种：保护最脆弱的人群。
Eur Respir Rev. 2021 Jan 13;30(159). doi: 10.1183/16000617.0258-2020. Print 2021 Mar 31.
8
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.巴洛沙韦玛波西利用于家庭接触者流感预防。
N Engl J Med. 2020 Jul 23;383(4):309-320. doi: 10.1056/NEJMoa1915341. Epub 2020 Jul 8.
9
Influenza-associated excess respiratory mortality in China, 2010-15: a population-based study.中国 2010-2015 年与流感相关的超额呼吸道死亡率：基于人群的研究。
Lancet Public Health. 2019 Sep;4(9):e473-e481. doi: 10.1016/S2468-2667(19)30163-X.
Zotero 插件